AR087999A1 - Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a - Google Patents
Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1aInfo
- Publication number
- AR087999A1 AR087999A1 ARP120103514A ARP120103514A AR087999A1 AR 087999 A1 AR087999 A1 AR 087999A1 AR P120103514 A ARP120103514 A AR P120103514A AR P120103514 A ARP120103514 A AR P120103514A AR 087999 A1 AR087999 A1 AR 087999A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- alkoxy
- group
- cyano
- Prior art date
Links
- YGKVYZJHZKYBLL-UHFFFAOYSA-N 1,6-dihydro-[1,2,4]triazolo[4,3-a][4,1]benzoxazepine Chemical compound O1CC2=CC=CC=C2N2CN=NC2=C1 YGKVYZJHZKYBLL-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 206010001488 Aggression Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000012761 aggressive behavior Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas que los contienen y su utilización como medicamentos. Los compuestos activos de la presente son útiles como agentes terapéuticos que actúan a nivel periférico y central en estados patológicos tales como la dismenorrea, disfunción sexual masculina y femenina, hipertensión, fallo cardíaco crónico, secreción inapropiada de vasopresina, cirrosis hepática, síndrome nefrótico, ansiedad, trastornos depresivos, trastorno obsesivo-compulsivo, trastornos del espectro autista, esquizofrenia y conducta agresiva. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R¹ es halógeno y R² se elige entre el grupo formado por i) heteroarilo, sin sustituir o sustituido por 1 - 3 sustituyentes elegidos individualmente entre el grupo formado por OH, halógeno, ciano, alquilo C₁₋₆, alcoxi C₁₋₆, halógeno-alquilo C₁₋₆, halógeno-alcoxi C₁₋₆, (alcoxi C₁₋₆)-alquilo C₁₋₆ e hidroxi-alquilo C₁₋₆; ii) arilo, sin sustituir o sustituido por 1 - 3 sustituyentes elegidos individualmente entre el grupo formado por OH, halógeno, ciano, alquilo C₁₋₆, alcoxi C₁₋₆, halógeno-alquilo C₁₋₆, halógeno-alcoxi C₁₋₆, (alcoxi C₁₋₆)-alquilo C₁₋₆ e hidroxi-alquilo C₁₋₆; iii) cicloalquilo C₃₋₇, sin sustituir o sustituido por 1 - 3 sustituyentes elegidos individualmente entre el grupo formado por OH, halógeno, ciano, alquilo C₁₋₆, alcoxi C₁₋₆, halógeno-alquilo C₁₋₆, halógeno-alcoxi C₁₋₆, (alcoxi C₁₋₆)-alquilo C₁₋₆ e hidroxi-alquilo C₁₋₆; y iv) alquilo C₁₋₆, sin sustituir o sustituido por 1 - 3 sustituyentes elegidos individualmente entre el grupo formado por OH, halógeno, ciano, alcoxi C₁₋₆ y halógeno-alcoxi C₁₋₆; o sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11182796 | 2011-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087999A1 true AR087999A1 (es) | 2014-04-30 |
Family
ID=46881068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103514A AR087999A1 (es) | 2011-09-26 | 2012-09-25 | Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8828989B2 (es) |
| EP (1) | EP2760871B1 (es) |
| JP (1) | JP5909554B2 (es) |
| KR (1) | KR101682777B1 (es) |
| CN (1) | CN103827121B (es) |
| AR (1) | AR087999A1 (es) |
| AU (1) | AU2012314593B2 (es) |
| BR (1) | BR112014006945A2 (es) |
| CA (1) | CA2844581A1 (es) |
| CL (1) | CL2014000717A1 (es) |
| CO (1) | CO6870036A2 (es) |
| CR (1) | CR20140092A (es) |
| EA (1) | EA024990B1 (es) |
| EC (1) | ECSP14013271A (es) |
| IN (1) | IN2014CN02169A (es) |
| MA (1) | MA35535B1 (es) |
| MX (1) | MX2014003643A (es) |
| PE (1) | PE20141397A1 (es) |
| PH (1) | PH12014500582A1 (es) |
| SG (1) | SG2014010607A (es) |
| TW (1) | TWI553013B (es) |
| UA (1) | UA111623C2 (es) |
| WO (1) | WO2013045373A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4185570B1 (en) * | 2020-07-23 | 2024-10-09 | F. Hoffmann-La Roche AG | Cyclohexyl substituted triazoles as vasopressin receptor v1a antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1147115E (pt) | 1999-01-19 | 2004-02-27 | Ortho Mcneil Pharm Inc | Benzodiazepinas triciclicas como antagonistas do receptor da vasopressina |
| US6765004B1 (en) | 1999-06-17 | 2004-07-20 | Ortho-Mcneil Pharmaceutical, Inc. | Indoloazepines as vasopressin receptor antagonists |
| US7119088B2 (en) | 2003-02-19 | 2006-10-10 | Pfizer Inc. | Triazole compounds useful in therapy |
| GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| MX2007002248A (es) * | 2004-08-25 | 2008-10-02 | Pfizer | Triazolobenzodiazepinas y su uso como antagonistas de vasopresina. |
| PE20110590A1 (es) * | 2008-11-18 | 2011-08-31 | Hoffmann La Roche | Alquilciclohexileteres de dihidrotetraazabenzoazulenos |
| MY150837A (en) * | 2008-11-28 | 2014-02-28 | Hoffmann La Roche | Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists |
-
2012
- 2012-08-23 US US13/592,493 patent/US8828989B2/en active Active
- 2012-09-24 KR KR1020147010783A patent/KR101682777B1/ko not_active Expired - Fee Related
- 2012-09-24 MX MX2014003643A patent/MX2014003643A/es unknown
- 2012-09-24 BR BR112014006945A patent/BR112014006945A2/pt not_active IP Right Cessation
- 2012-09-24 CA CA2844581A patent/CA2844581A1/en not_active Abandoned
- 2012-09-24 CN CN201280046689.0A patent/CN103827121B/zh not_active Expired - Fee Related
- 2012-09-24 JP JP2014532331A patent/JP5909554B2/ja not_active Expired - Fee Related
- 2012-09-24 UA UAA201403611A patent/UA111623C2/uk unknown
- 2012-09-24 EA EA201490558A patent/EA024990B1/ru not_active IP Right Cessation
- 2012-09-24 WO PCT/EP2012/068721 patent/WO2013045373A1/en not_active Ceased
- 2012-09-24 IN IN2169CHN2014 patent/IN2014CN02169A/en unknown
- 2012-09-24 AU AU2012314593A patent/AU2012314593B2/en not_active Ceased
- 2012-09-24 PE PE2014000394A patent/PE20141397A1/es not_active Application Discontinuation
- 2012-09-24 SG SG2014010607A patent/SG2014010607A/en unknown
- 2012-09-24 PH PH1/2014/500582A patent/PH12014500582A1/en unknown
- 2012-09-24 EP EP12761740.5A patent/EP2760871B1/en active Active
- 2012-09-25 TW TW101135168A patent/TWI553013B/zh not_active IP Right Cessation
- 2012-09-25 AR ARP120103514A patent/AR087999A1/es unknown
-
2014
- 2014-01-31 CO CO14020668A patent/CO6870036A2/es not_active Application Discontinuation
- 2014-02-26 CR CR20140092A patent/CR20140092A/es unknown
- 2014-03-24 CL CL2014000717A patent/CL2014000717A1/es unknown
- 2014-03-26 EC ECSP14013271 patent/ECSP14013271A/es unknown
- 2014-04-15 MA MA36919A patent/MA35535B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201490558A1 (ru) | 2014-06-30 |
| CL2014000717A1 (es) | 2014-10-03 |
| CR20140092A (es) | 2014-03-20 |
| EA024990B1 (ru) | 2016-11-30 |
| IN2014CN02169A (es) | 2015-05-29 |
| ECSP14013271A (es) | 2014-05-31 |
| MA35535B1 (fr) | 2014-10-02 |
| CA2844581A1 (en) | 2013-04-04 |
| CN103827121A (zh) | 2014-05-28 |
| AU2012314593B2 (en) | 2016-09-29 |
| TW201315737A (zh) | 2013-04-16 |
| US20130079333A1 (en) | 2013-03-28 |
| WO2013045373A1 (en) | 2013-04-04 |
| JP5909554B2 (ja) | 2016-04-26 |
| KR101682777B1 (ko) | 2016-12-05 |
| AU2012314593A1 (en) | 2014-02-20 |
| EP2760871A1 (en) | 2014-08-06 |
| MX2014003643A (es) | 2014-04-30 |
| CO6870036A2 (es) | 2014-02-20 |
| AU2012314593A8 (en) | 2014-03-27 |
| UA111623C2 (uk) | 2016-05-25 |
| KR20140079790A (ko) | 2014-06-27 |
| EP2760871B1 (en) | 2018-07-18 |
| US8828989B2 (en) | 2014-09-09 |
| TWI553013B (zh) | 2016-10-11 |
| PH12014500582A1 (en) | 2014-04-28 |
| PE20141397A1 (es) | 2014-10-13 |
| CN103827121B (zh) | 2016-08-03 |
| SG2014010607A (en) | 2014-05-29 |
| NZ620653A (en) | 2016-03-31 |
| JP2014527993A (ja) | 2014-10-23 |
| BR112014006945A2 (pt) | 2017-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080955A1 (es) | Aril-/heteroaril-ciclohexenil-tetraazabenzo(e)azulenos | |
| ECSP12012291A (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos | |
| AR086522A1 (es) | Inhibidores heterociclicos de autotaxina y usos de los mismos | |
| CO6640209A2 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas del receptor v1a de la vasopresina | |
| AR080733A1 (es) | Aril-ciclohexil-tetraazabenzo[e]azulenos, un proceso para su obtencion, una composicion farmaceutica que los contiene y su uso para la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el antagonismo del receptor de v1a | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| UY33353A (es) | Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion | |
| CO6341478A2 (es) | Arilciclohexileteres de dihidro-tetraazabenzoazulenos para su uso como antagonistas del receptor v1a de vasopresina | |
| AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
| EA201492023A1 (ru) | Регуляторы пути комплемента и их применение | |
| AR074354A1 (es) | Alquilciclohexileteres de dihidrotetraazabenzoazulenos, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| MD20140119A2 (ro) | Agenţi pentru tratarea afecţiunilor care implică modularea receptorilor de rianodină | |
| EA201492170A1 (ru) | Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| MX2012013206A (es) | Inhibidores de quinasa biciclica fusionada. | |
| ECSP12012209A (es) | HETEROBIARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS | |
| MX2014003600A (es) | Ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas v1a. | |
| MX2019000103A (es) | Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc). | |
| AR081964A1 (es) | Derivados aminoester de alcaloides y composiciones medicinales de los mismos | |
| AR087999A1 (es) | Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a | |
| AR076942A1 (es) | Derivados de amidas del acido 6,7-dihidro-5h-imidazo(1,2-a)imidazol-3-carboxilico | |
| CO6630104A2 (es) | Derivados de quinolizidina e indolizidina | |
| ES2458933B1 (es) | Derivados ciclofánicos de bis-piridinio como fármacos anti-protozoarios | |
| EA201171010A1 (ru) | Производные 6-(6-o-циклоалкил- или 6-nh-циклоалкилтриазолопиридазинсульфанил)бензотиазолов и бензимидазолов: способ получения, применение в качестве лекарственных средств и применение в качестве ингибиторов met | |
| TH172318A (th) | สารประกอบกรดไดคาร์บอกซิลิค |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |